(Date:7/3/2009)... Upstate HomeCare, a home medical services pr...ion, respiratory and DME services, is expanding. T...e specializes in home infusion therapy and one in ...meCare. , Clinton, NY (PR...edical services provider specializing in infusion,...
(Date:7/2/2009)...apore,s Bioprocessing Technology Institute (BTI) h...s-apoptosis inhibitory molecule" (FAIM), protects ...grammed cell death. , Their research is publish...tiation . , The scientists, Jianxin Huo, Ph.D., ...rocess may possibly be manipulated for clinical ap...
(Date:7/2/2009)... Recent news reports hav...als and ensuring that physicians meet high standar...the American Board of Medical Specialties (ABMS), ... in their efforts to develop and implement educati... and certification of physician specialists. Cert...
(Date:7/2/2009)... Pro-life forces won an ...ourt ruled to uphold a state law regulating that a...s in administering RU-486 (also known as the "abor...n using the drug. , , The ruling came in Roge...Parenthood to a 2004 law requiring that those admi...
Breaking Medicine News(10 mins):Health News:Upstate HomeCare Expands, Adds Pharmacies 2Health News:Upstate HomeCare Expands, Adds Pharmacies 3Health News:Gene's novel role may provide key to treating liver and neurodegenerative diseases 2Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 2Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 3Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 4Health News:Ohio Supreme Court Strikes a Blow to Planned Parenthood in Upholding Regulation of 'Abortion Pill' 2(Date:6/26/2009)...Cancer Recurrence Test MammaPrint,Included in Int...ions" issued,on 23 Jun 2009 12:00 GMT, by Agendia...e subheadline was missing from the release as inco...rected release follows: , , /PRNewswire/...st MammaPrint Included in,International St. Galle...
(Date:6/25/2009)...to Attend First National Symposium - , , CORTLA...al symposium designed to explore the health impact...ork City when thirteen top experts gather to prese...lds. The SUNY Youth Sports Institute will gather ...t the $5 billion-a-year energy drink industry has ...
(Date:6/25/2009)...CE for Once-Daily Treatment of Pseudomonas Lung In...PRNewswire/ -- Cystic Fibrosis Foundation Therapeu...ibrosis Foundation, has provided a $2.2 million aw...t of ARIKACE(TM) (liposomal amikacin for inhalatio... lung infections in cystic fibrosis (CF) and non-C...
(Date:6/24/2009)...rstCall/ -- , - Recruitment on Track for Th...eatment of Eye Disease With No Reported Safety Iss...THR), a biotechnology company,focused on the disc... eye,disease, vascular disease and cancer, announ...ch is in Phase III trials for the treatment of vit...
Breaking Medicine Technology:/C O R R E C T I O N -- Agendia B.V./ 2/C O R R E C T I O N -- Agendia B.V./ 3SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 2SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 3SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 4Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 2Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 3Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 4ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule 2ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule 3Labopharm receives FDA response to appeal of Approvable Letter for once daily tramadol 6768 1Labopharm receives FDA response to appeal of Approvable Letter for once daily tramadol 6768 2Brostallicin Trial Data Demonstrates Encouraging Anti tumor Activity in Patients With Chemotherapy Resistant Cancers 1894 1Brostallicin Trial Data Demonstrates Encouraging Anti tumor Activity in Patients With Chemotherapy Resistant Cancers 1894 2Brostallicin Trial Data Demonstrates Encouraging Anti tumor Activity in Patients With Chemotherapy Resistant Cancers 1894 3SARS 3A a model disease 6766 1SARS 3A a model disease 6766 2UFs new owl butterfly species naming rights auctioned for 2440 800 1296 1UFs new owl butterfly species naming rights auctioned for 2440 800 1296 2UFs new owl butterfly species naming rights auctioned for 2440 800 1296 3...r 20, 2007 - MGI PHARMA, INC.,(NASDAQ: MOGN), a bi...ute care, today announced that a randomized, doubl...uavan(R) (fospropofol,disodium) Injection for seda...lly met its primary endpoint of sedation,success a...who,received an initial bolus dose of 6.5 mg/kg of...
...)--Mar 20, 2007 - Arrowhead,Research Corporation (...ubsidiary Calando Pharmaceuticals has published,re...f Sciences,(PNAS) of the first non-human primate s...,s lead siRNA therapeutic candidate., Calando is u...meric delivery systems and siRNA design to create ...
Other Medicine Technology:MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 2MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 3MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 4MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 5MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 6Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 2Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 3VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (
Medicine Products: